Second-line drug susceptibilities of Thai multidrug-resistant Mycobacterium tuberculosis isolates.
The emergence of multidrug-resistant tuberculosis (MDR-TB) is increasing and is exacerbated by the human immunodeficiency virus (HIV) epidemic. The standard short-course regimen used for the treatment of tuberculosis is likely to be ineffective against MDR-TB, leading to the need for second-line drugs. In such situations, drug susceptibility testing (DST) is necessary to select an appropriate treatment regimen. In this study, DST of 99 MDR-TB strains isolated in Thailand was performed using a drug-impregnated disc method. The results showed that 94.95% of the strains were susceptible to amikacin and kanamycin, 90.91% to ciprofloxacin and ofloxacin, 85.86% to para-aminosalicylic acid, and 78.79% to ethionamide.
Prammananan
T
T
Drug-Resistant Tuberculosis Research Fund, Siriraj Foundation, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand.
Arjratanakool
W
W
Chaiprasert
A
A
Tingtoy
N
N
Leechawengwong
M
M
Asawapokee
N
N
Leelarasamee
A
A
Dhiraputra
C
C
D000583:Amikacin / Q000494:pharmacology; D010131:Aminosalicylic Acid / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D024901:Drug Resistance, Multiple, Bacterial; D005000:Ethionamide / Q000494:pharmacology; D007612:Kanamycin / Q000494:pharmacology; D008826:Microbial Sensitivity Tests / Q000379:methods; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D015242:Ofloxacin / Q000494:pharmacology; D013785:Thailand
D007612:Kanamycin; D010131:Aminosalicylic Acid; D002939:Ciprofloxacin; D000583:Amikacin; D015242:Ofloxacin; D005000:Ethionamide